ClinicalTrials.gg
CompletedNCT04086238Updated Jan 22, 2020

Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects

A Phase 1 interventional study of Decitabine in Healthy, sponsored by EpiDestiny, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-22.

Sponsored by EpiDestiny, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study is to investigate the effect of a high fat meal on the pharmacokinetics of decitabine and THU in healthy adults when administered as a modified release formulation of the 2 drugs in combination.

Read the detailed description

This study is to evaluate the relative pharmacokinetics of oral decitabine and tetrahydrouridine (THU) after a high-fat, high-calorie (FDA standard) meal as compared to decitabine and THU under fasting conditions in healthy adult male and female subjects. In addition, this study is to compare the pharmacokinetic parameters between male and female subjects, and also to capture safety information for the decitabine and THU combination in healthy subjects after oral dosing.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

EpiDestiny, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understands and voluntarily signs a written Form prior to any study related procedures being performed and is able to adhere to restrictions and examination schedules.
  • Able to communicate with the investigator, and to understand and comply with the requirements of the study.
  • A healthy male or female from any race between 18 to 50 years of age (inclusive). If female, she meets at least one of the following criteria: Surgically sterile (hysterectomy, tubal ligation or bilateral oophorectomy); Or ≥1 year (will have a follicle-stimulating hormone test performed at screening to confirm postmenopausal status)
  • A (BMI) between 18 and 30 kg/m2 (inclusive) and a minimum weight of 50 kg at screening.
  • Subjects must be free of any disease that would interfere with the study evaluations, and be in good health as determined by past medical history, physical examination, and at screening.
  • Vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the supine position after the subject has rested for at least 5 minutes. At screening, the potential subject must be afebrile, with a systolic blood pressure between 90 and 140 mmHg (inclusive), diastolic blood pressure between 60 and 90 mmHg (inclusive), and pulse rate between 50 and 100 bpm (inclusive).
  • Male subjects (including those who have had a documented vasectomy) must use a double-barrier local (i.e., spermicidal gel plus condom) when engaging in sexual activity with women of while on study medication and for 28 days after the last dose of study medication. They must also agree to refrain from sperm donations while on study drug, for the entire duration of the study, and for at least 28 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • History (within 3 years prior to screening) or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition, including the presence of laboratory abnormalities, that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
  • Any serious medical condition, clinically significant laboratory abnormality, or psychiatric illness that would prevent the subject from signing the Form.
  • Used any prescribed systemic or topical medication within 30 days of the first dose administration.
  • Used any non-prescribed systemic (including herbal medicines, e.g. St. John's Wort) or topical medication within 7 days of the first dose administration (with the exception of vitamin/mineral supplements)
  • Subjects who have any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism and excretion (ADME), including a past cholecystectomy.
  • Exposed to an drug (new chemical entity) within 90 days preceding the first dose administration or currently enrolled in any investigational trials.
  • Donated blood or plasma within 8 weeks preceding the first dose administration.
  • History of multiple drug allergies.
  • Any clinically significant allergic disease (excluding nonactive hayfever).
  • History of drug abuse within 2 years prior to dosing, or a positive drug test at screening or either check-in.
  • History of alcohol abuse within 2 years prior to dosing, or a positive alcohol test at screening or either check-in.
  • Smokers or users of other tobacco products (e.g., chewing tobacco, or those using nicotine-containing products (i.e., patches, gum) within 3 months prior to screening, or a positive urine cotinine test at screening or either check-in.
  • Known to have serum hepatitis or known to be a carrier of the surface antigen (HBsAg) or antibody, or tests positive for (human immunodeficiency virus) antibodies at screening.
  • Subject must not consume beverages and foods containing grapefruit, broccoli, poppy seeds, Brussels sprouts, pomegranate, star fruit, char-grilled meat, or caffeine/xanthine from 48 hours prior to the first dose of study medication until the end-of-study visit. Subjects will be instructed not to consume any of the above products; however, allowance for an isolated single incidental consumption may be evaluated and approved by the study investigator based on the potential for interaction with the study drug.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Other
    Formulation A Fasted

    EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.

    Drug: Decitabine

  • Experimental
    Formulation A Fed

    EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.

    Drug: Decitabine

  • Other
    Formulation B Fasted

    EPI01 Formulation B (slow reelase): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.

    Drug: Decitabine

  • Experimental
    Formulation B Fed

    EPI01 Formulation B (slow release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.

    Drug: Decitabine

  • Other
    Formulation C Fasted

    EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.

    Drug: Decitabine

  • Experimental
    Formulation C Fed

    EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.

    Drug: Decitabine

Interventions

  • Capsules containing a combination of decitabine and THU

    Also known as: EPI01, Tetrahydrouridine

06

What researchers measure

Primary outcomes

  1. Absorption of Decitabine

    Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration of Decitabine

    Time frame: 24 hours

  2. Decitabine plasma concentration

    Maximum concentration (Cmax) of Decitabine in plasma

    Time frame: 24 hours

  3. Absorption of Tetrahydrouridine

    Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration of THU

    Time frame: 24 hours

Secondary outcomes

  1. Safety of decitabine and tetrahydrouridine

    The number of subjects reporting adverse events such as nausea and headache.

    Time frame: 24 hours

07

Study locations

1 site
  • Worldwide Clinical Trial
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: No — Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Nov 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2019
First posted
Sep 11, 2019
StartActual
Oct 8, 2019
Primary completionActual
Nov 21, 2019
CompletionActual
Nov 30, 2019
Last update
Jan 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04086238
Lead sponsor
EpiDestiny, Inc.
Responsible party
Sponsor
First posted
Sep 11, 2019
Start date
Oct 8, 2019
Primary completion
Nov 21, 2019
Completion
Nov 30, 2019
Last update
Jan 22, 2020

Study contacts

Cynthia A Zamora, MD
principal investigator · Worldwide Clinical Trails Early Phase Services, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion